Chen Peiqi, Satterwhite Julie H, Licata Angelo A, Lewiecki E Michael, Sipos Adrien A, Misurski Derek M, Wagman Rachel B
Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
J Bone Miner Res. 2005 Jun;20(6):962-70. doi: 10.1359/JBMR.050105. Epub 2005 Jan 18.
The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied. Changes in five biochemical markers, obtained from a subset of women enrolled in the Fracture Prevention Trial, were examined. Early increases in the PICP and the PINP were the best predictors of BMD response to teriparatide in this analysis.
Early reductions in biochemical markers of bone turnover with antiresorptive therapy negatively correlate with subsequent increases in BMD. We undertook this analysis to determine if early changes in biochemical markers with teriparatide therapy predict subsequent increases in BMD.
In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day. Serum concentrations of two bone formation markers (bone-specific alkaline phosphatase [bone ALP] and the carboxy-terminal extension peptide of procollagen type 1 [PICP]) and urinary concentrations of two bone resorption markers (free deoxypyridinoline [DPD] and N-terminal telopeptide [NTX]) were assessed in a trial population subset (n = 520) at baseline and at 1, 3, 6, and 12 months. We also assessed serum concentrations of another bone formation marker, the amino-terminal extension peptide of procollagen type 1 (PINP), in a subset of 771 women at baseline and 3 months. Lumbar spine (LS) BMD was measured by DXA at baseline and 18 months. Femoral neck BMD was measured at baseline and 12 months.
Baseline bone turnover status correlated positively and significantly with BMD response. The highest correlations occurred for the LS BMD response to teriparatide 20 microg/day. Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p < 0.05). The relationships between these two biochemical markers and the LS BMD response were stronger than the corresponding relationships for the femoral neck BMD response. Using receiver operator curve analysis, we determined that the increases in PICP at 1 month and PINP at 3 months were the most sensitive and accurate predictors of the LS BMD response.
研究了绝经后骨质疏松症女性骨转换生化标志物的早期变化与随后每日接受特立帕肽治疗的骨密度反应之间的关系。对参加骨折预防试验的一部分女性的五种生化标志物变化进行了检测。在此分析中,血清前胶原I型羧基端前肽(PICP)和血清前胶原I型氨基端前肽(PINP)的早期升高是骨密度对特立帕肽反应的最佳预测指标。
抗吸收治疗使骨转换生化标志物早期降低与随后骨密度增加呈负相关。我们进行此项分析以确定特立帕肽治疗后生化标志物的早期变化是否可预测随后骨密度的增加。
在骨折预防试验中,1637名绝经后骨质疏松症女性被随机分组,分别每日自行皮下注射安慰剂、20μg/天特立帕肽或40μg/天特立帕肽。在一个试验人群亚组(n = 520)中,于基线及1、3、6和12个月时评估两种骨形成标志物(骨特异性碱性磷酸酶[骨ALP]和前胶原I型羧基末端延长肽[PICP])的血清浓度,以及两种骨吸收标志物(游离脱氧吡啶啉[DPD]和氨基末端肽[NTX])的尿浓度。我们还在771名女性亚组的基线及3个月时评估了另一种骨形成标志物——前胶原I型氨基末端延长肽(PINP)的血清浓度。在基线及18个月时通过双能X线吸收法(DXA)测量腰椎(LS)骨密度。在基线及12个月时测量股骨颈骨密度。
基线骨转换状态与骨密度反应呈显著正相关。腰椎骨密度对20μg/天特立帕肽的反应相关性最高。在所有研究的生化标志物中,1个月时PICP的升高和3个月时PINP的升高与18个月时腰椎骨密度的增加相关性最佳(分别为0.65和0.61;p < 0.05)。这两种生化标志物与腰椎骨密度反应之间的关系比与股骨颈骨密度反应的相应关系更强。使用受试者工作特征曲线分析,我们确定1个月时PICP的升高和3个月时PINP的升高是腰椎骨密度反应最敏感和准确的预测指标。